



CLAIMS

1. Pyridinylpyrazolopyrimidinone derivative represented by the following formula (IA) or (IB):



(IA)



(IB)

wherein:

R^1 is substituted or unsubstituted C_3 - C_8 cycloalkyl group or tert-butyl group;

R^2 is a hydrogen atom or C_1 - C_3 alkyl group;

R^3 is a group: $-NR^5R^6$, $-C(=O)R^7$ or $-S(O)_{0-2}R^8$;

R^4 is a hydrogen atom or C_1 - C_3 alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);

R^5 and R^6 are, same or different from each other, a hydrogen atom, substituted or unsubstituted C_1 - C_6 alkyl group, substituted or unsubstituted acyl group, substituted or unsubstituted heterocycloalkyl group, and substituted or unsubstituted heterocycloalkyl ring is formed with nitrogen atom which is binding R^5 and R^6 ;

R^7 is a group: $-OR^9$ or $-NR^5R^6$;

R^8 is a hydrogen atom, a halogen atom, a group: $-NR^5R^6$, substituted or unsubstituted C_1 - C_6 alkyl group, or substituted or unsubstituted aryl group;

R^9 is a hydrogen atom or substituted or unsubstituted C_1 - C_6 alkyl group;

or pharmaceutically acceptable salts or solvates thereof.

2. The compound represented by the formula (IA) according to claim 1.

3. The compound represented by the formula (IB) according to claim 1.

4. The compound according to claim 1, 2 or 3, in which R^1 is

cyclohexyl group or cycloheptyl group.

5. The compound according to any one of claims 1 to 4, in which R^2 is methyl group.

6. The compound according to any one of claims 1 to 5, in which
5 R^4 is methoxy or ethoxy group.

7. The compound according to any one of claims 1 to 6, in which R^3 is a group $-NR^5R^6$.

8. A pharmaceutical composition containing a compound according to any one of claims 1 to 7, or pharmaceutically acceptable salts or solvates
10 thereof as active ingredient.

9. A PDE 7 inhibitor containing a compound according to any one of claims 1 to 7, or pharmaceutically acceptable salts or solvates thereof as active ingredient.